Novel Therapeutic Strategies for Alzheimer’s Disease Treatment
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 25 May 2025 | Viewed by 1523
Special Issue Editor
Interests: ultrastructure; Alzheimer’s disease; cardiovascular disease; FOCM; hypertension; type 2 diabetes mellitus; metabolic syndrome; insulin and leptin resistance; neurovascular unit; endothelial cells; endothelial glycocalyx; reactive neuroglia; BBB; BCSF barrier; neuroinflammation; choroid plexus; perivascular spaces
Special Issue Information
Dear Colleagues,
Sporadic or late-onset Alzheimer’s disease (LOAD) is the most common multifactorial, progressive neurodegenerative disease that causes dementia globally. It is associated with aging (≥65 years of age) and increased morbidity and mortality. Currently, most therapies have utilized a single-target treatment protocol, and it is becoming more apparent that a multi-targeted approach or a combination approach may be necessary in order to attenuate, slow, or halt neurodegenerative disease progression as occurs in LOAD.
The primary goal of this Special Issue is to bring forth novel treatment strategies that may help to advance new paradigm treatments specifically for LOAD that may also have possible implications for other neurodegenerative diseases.
Reviews, case reports, or original research manuscripts will be considered.
Prof. Dr. Melvin Hayden
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Sporadic
- late-onset Alzheimer’s disease (LOAD)
- neurodegenerative diseases
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.